A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
provide enhanced security for the medical supply chain. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medical Supply Chain 
4
Security Act’’. 
5
SEC. 2. MEDICAL SUPPLY CHAIN SECURITY. 
6
(a) ADDITIONAL MANUFACTURER REPORTING FOR 
7
ESSENTIAL MEDICAL DEVICES.—Section 506C of the 
8
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356c) 
9
is amended— 
10
22:24 Mar 25, 2022
H7208
2 
•HR 7208 IH
(1) in subsection (a)— 
1
(A) in the matter preceding paragraph (1), 
2
by inserting ‘‘or device’’ after ‘‘a drug’’; and 
3
(B) in the flush matter by inserting ‘‘or 
4
device’’ after ‘‘drug’’ each place such term ap-
5
pears; 
6
(2) in subsection (c), by inserting ‘‘and devices’’ 
7
after ‘‘drugs’’; 
8
(3) in subsection (g)— 
9
(A) in the matter preceding paragraph (1), 
10
by striking ‘‘drug shortage of a drug’’ and in-
11
serting ‘‘shortage of a drug or device’’; 
12
(B) in paragraph (1), by striking ‘‘; or’’ 
13
and inserting a semicolon; 
14
(C) by redesignating paragraph (2) as 
15
paragraph (3); 
16
(D) by inserting after paragraph (1) the 
17
following: 
18
‘‘(2) expedite the review of a device subject to 
19
premarket approval under section 515 that could 
20
help mitigate or prevent such shortage; or’’; and 
21
(E) in paragraph (3), as so redesignated, 
22
by striking ‘‘drug shortage’’ and inserting 
23
‘‘shortage’’; 
24
(4) in subsection (h)— 
25
22:24 Mar 25, 2022
H7208
3 
•HR 7208 IH
(A) by amending paragraph (2) to read as 
1
follows: 
2
‘‘(2) the term ‘shortage’, with respect to a drug 
3
or device, means a period of time when the demand 
4
or projected demand for the drug or device within 
5
the United States exceeds the supply of the drug or 
6
device; and’’; and 
7
(B) in paragraph (3)(A), by inserting ‘‘or 
8
device’’ after ‘‘drug’’; and 
9
(5) by adding at the end the following: 
10
‘‘(k) ADDITIONAL MANUFACTURER REPORTING FOR 
11
ESSENTIAL DRUGS AND DEVICES.—Each manufacturer 
12
of a drug or device described in subsection (a) shall pro-
13
vide to the Food and Drug Administration, on an annual 
14
basis, or more frequently at the request of the Secretary, 
15
information related to the manufacturing capacity of such 
16
drug or device. Such information shall include— 
17
‘‘(1) details about— 
18
‘‘(A) all locations of production; 
19
‘‘(B) the sourcing of all component parts; 
20
‘‘(C) the sourcing of any active pharma-
21
ceutical ingredients; and 
22
‘‘(D) the use of any scarce raw materials; 
23
and 
24
22:24 Mar 25, 2022
H7208
4 
•HR 7208 IH
‘‘(2) any other information determined by the 
1
Secretary to be relevant to the security of the supply 
2
chain of the drug or device.’’. 
3
(b) PROVISION OF ADDITIONAL INFORMATION.—Sec-
4
tion 506C–1 of the Federal Food, Drug, and Cosmetic Act 
5
(21 U.S.C. 356c–1) is amended— 
6
(1) in the heading, by striking ‘‘DRUG SHORT-
7
AGES’’ and inserting ‘‘DRUG OR DEVICE SHORT-
8
AGES’’; 
9
(2) by striking ‘‘drug shortages’’ each place it 
10
appears and inserting ‘‘drug or device shortages’’; 
11
(3) in subsection (a)— 
12
(A) in paragraph (3)(B)— 
13
(i) in clause (i), by striking ‘‘section 
14
506C(g)(1)’’ and inserting ‘‘paragraph (1) 
15
or (2) of section 506C(g)’’; and 
16
(ii) in clause (ii), by striking ‘‘section 
17
506C(g)(2)’’ 
and 
inserting 
‘‘section 
18
506C(g)(3)’’; and 
19
(B) in paragraph (5), by striking ‘‘drug 
20
shortage’’ and inserting ‘‘drug or device short-
21
age’’; and 
22
(4) in subsection (c), by striking ‘‘ ‘drug short-
23
age’ or’’. 
24
Æ 
22:24 Mar 25, 2022
H7208
